Negocie BioNTech BNTX

Venda
 Comprar

Gráfico BioNTech ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

Últimas notícias

Frances Wang 2025 Apr 24, 16:00

How will tariffs affect forex: EUR/USD pair weakens amid trade uncertainty

Forex
Frances Wang 2025 Apr 24, 16:00

Exchange Traded Funds News: Tech-Focused ETFs Gain Traction Amid AI Boom

ETFs
Tommy Yap 2025 Apr 24, 16:00

Morning Note: US-China Trade Deadlock; Nvidia's AI Leap; Canada Votes

Morning Note CAD Forex
Frances Wang 2025 Apr 24, 16:00

Popular CFD trading platforms 2025: eToro, Plus500, IG, MT4, MT5 and more

CFD Trading
Frances Wang 2025 Apr 23, 16:00

Hang Seng Index Gains on Strong China GDP amid Trump Tariffs Uncertainty

Indices
Frances Wang 2025 Apr 23, 16:00

Forex news today: GBP/USD gains, USD/JPY declines, EUR/USD strengthens

Forex
Frances Wang 2025 Apr 23, 16:00

Trending stocks to watch: AMD, GOOG, NVDA, AMZN, MSFT

Stocks
Tommy Yap 2025 Apr 23, 16:00

Morning Note: Tariff Deadlock Grips US-China Trade; Alphabet's Report Looms; BOJ Dilemma

Morning Note Tech

Info

Spread

0.8925

Spread (%)

0.7439 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercados fechados

Sexta-feira

13:31 - 19:59

Segunda-feira

13:31-19:59

Terça-feira

13:31-19:59

Quarta-feira

13:31-19:59

Quinta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

27604328448

Ações em circulação

240392992

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

2022-06-17

Data Ex-Dividendos

2022-06-02

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-3.47

Saiba mais sobre este instrumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados
Trustpilot